Needham Rates Revolution Medicines (RVMD) buy, $235 Price Target

Needham has reiterated its buy rating for Revolution Medicines, Inc. with a price target of $235, a 25.48% upside from the current price.

By TradeTexts Research Desk · Published Jun 29, 2026, 7:01 AM EDT · Updated Jul 1, 2026, 8:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Needham rated Revolution Medicines, Inc. ($RVMD) "buy" with a $235 price target on June 29, 2026.

Since the rating, $RVMD is down 1.4% after 1 week, down 6.1% after 1 month and down 7.6% to date (from the $192.62 close on Jun 29, 2026).

RVMD Revolution Medicines, Inc.

$177.96 +125.21% year to date

Daily close · Oct 16, 2026

Key Points

On June 29, 2026, Needham reiterated its buy rating for Revolution Medicines, Inc. (RVMD) with a price target of $235.
Needham's $235 price target implies 25.48% upside from Revolution Medicines, Inc.'s ($RVMD) current $187.28 share price.
Shares of RVMD traded near $182.08 on Monday with a market cap of approximately $38.7 billion and a 52-week range of $34.00 to $184.39.
Insider activities included CFO Anders Jack's planned sale and purchase of shares, and analyst consensus remains strong buy with a target mean price of $188.57.

Get $RVMD trade alerts by text

We text you when insiders, Congress or big funds trade $RVMD. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Revolution Medicines, Inc. alert may contain errors. Disclosures

Needham reiterated its buy rating for Revolution Medicines, Inc. (NasdaqGS: RVMD) on June 29, 2026, maintaining a price target of $235. The analyst behind this decision, Ami Fadia, continues to see potential in the company's stock. On the same day, shares of Revolution Medicines traded near $182.08.

Analyst rating track record

Needham vs. the S&P 500

YTD return +14.94% hypothetical

All-time return +83.15% S&P 500 +25.59%

vs. S&P 500 +57.56% ahead of the index

Hypothetical returns from Needham's disclosed trades, not real profit or advice. How we model this.

Revolution Medicines, Inc. Stock Down 1.9%

Shares of Revolution Medicines, Inc. traded around $182.08 on Monday. The company, which is part of the biotechnology sector, has a market cap of approximately $38.7 billion. It is not currently profitable and has no meaningful P/E ratio. The stock's 52-week range is $34.00 to $184.39, and it has a 50-day moving average of $151.23 and a 200-day moving average of $98.50. The company maintains a strong current ratio of 6.80 and a quick ratio of 6.59, with a debt-to-equity ratio of 29.15.

12-month forecast

$RVMD price target

Revolution Medicines, Inc. daily closes and this analyst's $235 target. Not advice.

Insider Buying and Selling at Revolution Medicines, Inc.

Recent insider activity at Revolution Medicines includes transactions by CFO Anders Jack, who executed both planned sales and unplanned purchases on June 24, 2026. Jack sold 20,000 shares at an average price of $168.33 under a Rule 10b5-1 plan. On the same day, he also bought 20,000 shares at $18.56 and another 20,000 shares at no cost. Other insiders, including Lorence Kim, Flavia Borellini, and Sushil Patel, each acquired shares on June 18, 2026, without incurring a purchase price.

Analysts Set New Price Targets

On June 29, 2026, Needham maintained its buy rating on Revolution Medicines, setting a price target of $235. Other analysts have also shown optimism. Evercore ISI Group and RBC Capital maintained their buy ratings earlier in June, with respective targets of $220 and $182. The consensus among analysts is a strong buy, with a mean price target of $188.57 based on 21 analyst opinions.

About Revolution Medicines, Inc.

Revolution Medicines, Inc. is a biotechnology company based in Redwood City, California. It focuses on developing targeted therapies for RAS-addicted cancers. The company is known for its RAS(ON) inhibitors, which are designed to be used alone or in combination with other treatments. Revolution Medicines is led by Dr. Mark A. Goldsmith, M.D., Ph.D., and employs around 883 people.

Bottom Line

Investors closely watch Revolution Medicines, Inc. as analysts like Needham reaffirm their confidence in the stock. The repeated buy rating and high price target suggest continued optimism. However, as with all 13F filings and analyst ratings, remember they reflect past assessments and may not indicate current positions or future outcomes.